In this study, we have demonstrated the ability of the new anti-EMMPRIN monoclonal antibody hMR18-mAb to inhibit the activation of the EMT program and induce dormancy in three tumor cell lines of breast cancer and oral squamous cell carcinoma (OSCC). Here, BSG is linked to oral cavity squamous cell carcinoma.